Lifecare strengthens miniaturisation roadmap with new patent applications
24 september, 07:00
Bergen, Norway, 24 September 2025 – Lifecare ASA (LIFE), a MedTech company developing next-generation continuous glucose monitoring (CGM) technology, announces that new patent applications have been filed in Europe and the United States related to surface acoustic wave (SAW) sensing for osmotic glucose measurement.
SAW sensors are tiny chips that detect extremely small surface vibrations and are already widely used in other industries. When combined with Lifecare’s proprietary osmotic principle – where glucose levels are reflected as pressure changes – SAW sensors provide an additional way to measure these changes in very small devices.
This technology strengthens Lifecare’s roadmap towards further miniaturisation of implantable sensors. The company’s first product generation is based on proven, commercially available piezoresistive pressure sensors, ensuring size, reliability, and manufacturability for today’s needs.
Alongside Lifecare’s licensed Nano Tunneling Resistor (NTR) technology, SAW represents an alternative option for future miniaturisation – with the potential to improve sensitivity while supporting standardised production methods for faster development.
The patent applications have been filed by Lifecare’s academic partner Johann Wolfgang Goethe University Frankfurt, under a framework that grants Lifecare defined R&D rights and an option to secure commercial rights. The European application (EP 4 619 744) is scheduled for publication in the European Patent Bulletin on 24 September 2025.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
Attachments
Lifecare strengthens miniaturisation roadmap with new patent applications
Ämnen i artikeln
Lifecare strengthens miniaturisation roadmap with new patent applications
24 september, 07:00
Bergen, Norway, 24 September 2025 – Lifecare ASA (LIFE), a MedTech company developing next-generation continuous glucose monitoring (CGM) technology, announces that new patent applications have been filed in Europe and the United States related to surface acoustic wave (SAW) sensing for osmotic glucose measurement.
SAW sensors are tiny chips that detect extremely small surface vibrations and are already widely used in other industries. When combined with Lifecare’s proprietary osmotic principle – where glucose levels are reflected as pressure changes – SAW sensors provide an additional way to measure these changes in very small devices.
This technology strengthens Lifecare’s roadmap towards further miniaturisation of implantable sensors. The company’s first product generation is based on proven, commercially available piezoresistive pressure sensors, ensuring size, reliability, and manufacturability for today’s needs.
Alongside Lifecare’s licensed Nano Tunneling Resistor (NTR) technology, SAW represents an alternative option for future miniaturisation – with the potential to improve sensitivity while supporting standardised production methods for faster development.
The patent applications have been filed by Lifecare’s academic partner Johann Wolfgang Goethe University Frankfurt, under a framework that grants Lifecare defined R&D rights and an option to secure commercial rights. The European application (EP 4 619 744) is scheduled for publication in the European Patent Bulletin on 24 September 2025.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
Attachments
Lifecare strengthens miniaturisation roadmap with new patent applications
Ämnen i artikeln
Trumps tullar
-992x558.webp&w=3840&q=75)
Bolåneräntorna
.jpg&w=3840&q=75)
Analytikernas råd
Trumps tullar
Mest läst
Bolåneräntorna
Analytikernas råd
Senaste nytt
Marknadsöversikt
OMX Stockholm 30
1 DAG %
0,80%
Senast
2 644,62
1 mån
Loading market data...
